News
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2
NanoViricides, Inc. to present NV-387, a revolutionary broad-spectrum antiviral drug, at Pharma Partnering Summit 2025. NV-387 mimics virus features to combat viral infections effectively -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes -
-
